NCT00460460

TerminatedPhase 1

Phase I, Open-label, Dose Escalation of AZD4877 in Hematolog...

AstraZeneca Source

AstraZeneca

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

D2782C00002

Study Type

interventional

Estimated enrollment

75

Locations

2 countries

Sites

3

Timeline

Study Start

March 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

August 2007

Actual (reported)

Brief Summary

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: terminated
Estimated enrollment: 75 participants
Study completion date: August 2007
Actual (reported)
Listed locations: 2 countries · 3 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
March 2007
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
April 12, 2007
Actual (reported)
First Posted
April 16, 2007
Actual (reported)
Study Completion
August 2007
Actual (reported)

Last Updated: January 25, 2011
Status Verified: January 2011
Last Update Submitted: January 24, 2011

Conditions

Lymphoma

Keywords

Phase IcancerlymphomaleukemiamyelomaAMLALLNHLMM

Interventions

AZD4877Drug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients with AML, a certain type of ALL, NHL and MM
certain types of cancer of the lymph nodes

Sponsors & Collaborators

AstraZeneca
Industrylead

Study Sites (3)

Research site

Buffalo, New York, United States

Research Site

New York, New York, United States

Research Site

Toronto, Ontario, Canada

MeSH Terms

Conditions

LymphomaNeoplasmsLeukemiaNeoplasms, Plasma Cell

Interventions

N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesHematologic Diseases

Study Officials

Judith Ochs, MD
AstraZeneca
STUDY DIRECTOR

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

April 12, 2007

First Posted

April 16, 2007

Study Start

March 2007

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

August 2007

Actual (reported)

NCT00569985

Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma

Phase 1Completed

NCT00587015

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

Phase 1Terminated

NCT00893464

A Study of IXAZOMIB in Adult Patients With Lymphoma

Phase 1Completed

NCT00561756

Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma

Phase 1Completed

NCT00369629

Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

Phase 1Terminated

NCT00334438

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

Phase 1Completed

certain types of leukemias (blood cancers)

disease has or will fail with other treatments

relatively good overall health other than your cancer

You may not qualify if:

poor bone marrow function (not producing enough blood cells)
serious heart conditions
poor liver or kidney function

Contact the study team to confirm eligibility.

Last Updated

January 25, 2011

Record last verified: 2011-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00460460
Data provider: ClinicalTrials.gov
Source updated: 2011-01-25
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:17 UTC

Locations

CA(1)US(2)

Study Stopped

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations